UroGen Pharma Ltd (URGN) — Cash Flow Reinvestment Rate

Latest as of September 2017: 13.87x

UroGen Pharma Ltd (URGN) has a Cash Flow Reinvestment Rate of 13.87x as of September 2017, reinvesting $36.02 Million (capex $20.00K plus investments $-36.00 Million) from operating cash flow of $2.60 Million. Check cash flow quality index of UroGen Pharma Ltd to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

13.87x
(Capex + Investments) / Operating CF

Total Reinvested

$36.02 Million
Capex + Investments

Operating Cash Flow

$2.60 Million
USD

Capital Expenditures

$20.00K
USD

UroGen Pharma Ltd Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for UroGen Pharma Ltd across 1 annual periods. Explore URGN long-term investments to assets to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for UroGen Pharma Ltd (2016–2016)

Year-by-year capital reinvestment analysis for UroGen Pharma Ltd. For live market cap and broader valuation context, see UroGen Pharma Ltd (URGN) total market value.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2016 0.36x $1.49 Million $4.19 Million $695.00K —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow